amgen meritade glp-1 activity duration ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY| Amgen New weight loss drug innovations

The first few years after I was sick, I volunteered to meet with newly diagnosed cancer patients so they could talk to a survivor

The combined primary endpoint of death from cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke occurred in 569 (6.5%) of patients in the semaglutide group versus 701 (8.0%) of patients in the placebo group, yielding a significant hazard ratio of 0.8 for a 20% relative risk reduction

Others included MCAS patients who benefited from low doses of the drug

Li N, Liu BW, Ren WZ, Liu JX, Li SN, Fu SP, Zeng YL, Xu SY, Yan X, Gao YJ, Liu DF, Wang W (2016) GLP-2 attenuates LPS-induced inflammation in BV-2 cells by inhibiting ERK1/2, JNK1/2 and NF-B signaling pathways